BioNTech SE - American Depositary Shares (BNTX)
108.97
+0.00 (0.00%)
NASDAQ · Last Trade: Jun 10th, 7:06 AM EDT
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.
Via Benzinga · June 10, 2025
Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust."
Via Stocktwits · June 10, 2025
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition.
Via Investor's Business Daily · June 9, 2025

Via Benzinga · June 5, 2025

Via Benzinga · June 3, 2025

Wall Street Climbs Despite Trade Tensions: Steel Stocks Shine, Apple Impresses
Via Chartmill · June 3, 2025

Bristol Myers Squibb just agreed to shower BioNTech with cash.
Via The Motley Fool · June 2, 2025

BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion.
Via Benzinga · June 2, 2025

BMS will pay BioNTech $1.5 billion in an upfront payment in the second quarter and $2 billion in non-contingent anniversary payments through 2028.
Via Stocktwits · June 2, 2025

Via Benzinga · June 2, 2025
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.
Via Benzinga · May 27, 2025
The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter clinical trial requirements for healthy adults.
Via Benzinga · May 21, 2025
Shares of Vaccine stocks are moving higher on Tuesday after documents from the U.S. Food and Drug Administration revealed that its advisers will meet this week.
Via Benzinga · May 20, 2025
The new framework limits future Covid shots to people age 65 and older and those six months and older with a risk factor for serious illness.
Via Investor's Business Daily · May 20, 2025
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.
Via Benzinga · May 19, 2025
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase risk of severe illness.
Via Benzinga · May 19, 2025
The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio?
Via Benzinga · May 11, 2025
Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves.
Via Chartmill · May 7, 2025
BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion.
Via Benzinga · May 5, 2025
There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are hiding in plain sight.
Via The Motley Fool · May 1, 2025
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting other manufacturers.
Via Benzinga · April 29, 2025